A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab
Recruiting · NCT07607678 · Registry updated 2026-09-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab | Advanced Solid Cancer; Metastatic Solid Cancer | Recruiting | Phase 1 | 2026-09-29 | NCT07607678 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Boehringer Ingelheim | 158 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Clínica Universidad de Navarra | Pamplona | Spain | 12 |
| Hackensack University Medical Center | Hackensack | United States | 308 |
| Hospital Clinico Universitario de Valencia | Valencia | Spain | 109 |
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | 200 |
| National Cancer Center Hospital | Tokyo, Chuo-ku | Japan | 15 |
| National Cancer Center Hospital East | Chiba, Kashiwa | Japan | 13 |
| New York University Langone Medical Center | New York | United States | 23 |
| Scri Oncology Partners | Nashville | United States | 156 |
| Yale Cancer Center | New Haven | United States | 21 |